Arrowhead Pharmaceuticals, Inc.ARWRNASDAQ
Loading
Revenue Growth Under PressureDecelerating
Percentile Rank59
3Y CAGR-68.9%
5Y CAGR-56.0%
Year-over-Year Change
Year-over-year revenue growth rate
3Y CAGR
-68.9%/yr
vs +270.0%/yr prior
5Y CAGR
-56.0%/yr
Recent deceleration
Acceleration
-338.9pp
Decelerating
Percentile
P59
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 2.95% |
| Q3 2025 | 823.66% |
| Q2 2025 | -94.88% |
| Q1 2025 | 21608.36% |
| Q4 2024 | -89.40% |
| Q3 2024 | 0.00% |
| Q2 2024 | 0.00% |
| Q1 2024 | -100.00% |
| Q4 2023 | -77.94% |
| Q3 2023 | 1.72% |
| Q2 2023 | -89.18% |
| Q1 2023 | 133.86% |
| Q4 2022 | 98.09% |
| Q3 2022 | -2.58% |
| Q2 2022 | -78.65% |
| Q1 2022 | 453.25% |
| Q4 2021 | -28.33% |
| Q3 2021 | -16.58% |
| Q2 2021 | 39.86% |
| Q1 2021 | 54.02% |
| Q4 2020 | 179.10% |
| Q3 2020 | -72.12% |
| Q2 2020 | 16.35% |
| Q1 2020 | -20.12% |
| Q4 2019 | -31.96% |
| Q3 2019 | 1.40% |
| Q2 2019 | -11.32% |
| Q1 2019 | 38.92% |
| Q4 2018 | 207.93% |
| Q3 2018 | 1447.34% |
| Q2 2018 | 11.88% |
| Q1 2018 | -81.48% |
| Q4 2017 | -59.72% |
| Q3 2017 | -6.73% |
| Q2 2017 | 3.97% |
| Q1 2017 | 105.84% |
| Q4 2016 | 13869.59% |
| Q3 2016 | -21.05% |
| Q2 2016 | -9.52% |
| Q1 2016 | 0.00% |